- |||||||||| lopinavir/ritonavir / Generic mfg.
Journal: Fighting COVID-19. (Pubmed Central) - Aug 8, 2020
We conclude that, at this time of emergency, the search for new therapies is more urgent due to the need to save lives. Thus, we point out as interesting targets for future more specific research: glycoprotein S, Mpro, and TMPRSS2.
- |||||||||| hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Treatment for COVID-19 in High-Risk Adult Outpatients (clinicaltrials.gov) - Aug 7, 2020
P2/3, N=231, Active, not recruiting,
Thus, we point out as interesting targets for future more specific research: glycoprotein S, Mpro, and TMPRSS2. Recruiting --> Active, not recruiting | N=630 --> 231 | Trial primary completion date: Jul 2020 --> Oct 2020
- |||||||||| lopinavir/ritonavir / Generic mfg.
Journal, Benefit-risk assessment: Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. (Pubmed Central) - Aug 6, 2020
There was a reduction in acute respiratory distress syndrome with lopinavir-ritonavir in one study. Overall, the benefit-risk profile for lopinavir-ritonavir in severe COVID-19 cannot be considered positive until further efficacy and effectiveness data become available.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts. (Pubmed Central) - Aug 6, 2020
In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab. We have tabulated available data on various clinical trials testing various aspects of COVID-19 therapeutics.
- |||||||||| Soliris (eculizumab) / Alexion Pharma, lopinavir/ritonavir / Generic mfg.
Review, Journal: nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. (Pubmed Central) - Aug 6, 2020
Furthermore, a combination of hydroxychloroquine (i.e., 200 mg 3 times/day) and azithromycin (i.e., 500 mg on first day, then 250 mg/day from day 2-5) also exhibited good activity...Thus, in this article, we have analyzed the genetic diversity and molecular pathogenesis of nCOVID-19. We also present possible therapeutic options for nCOVID-19 patients.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Quadruple therapy for asymptomatic COVID-19 infection patients. (Pubmed Central) - Aug 5, 2020
Arbidol instruction dose may not be sufficient to inhibit the novel coronavirus in vivo. The evidence-based medicine of Lianhuaqingwen granules for treating various viral infections is just based on Chinese patients.
- |||||||||| efavirenz / Merck (MSD), Generic mfg., lopinavir/ritonavir / Generic mfg.
Retrospective data, Journal: Impact of Lopinavir/ritonavir-and Efavirenz-based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-naïve Patients in Beijing: A Retrospective Study. (Pubmed Central) - Aug 2, 2020
Both LPV/r or EFV treatment regimens impacted patients' lipid profile. Compared to EFV-based regimens, patients on LPV/r-based regimens had increased odds of dyslipidemia, such as hypercholesterolemia, hypertriglyceridemia, or high TC/HDL-C ratio; however, there was no obvious effect on LDL-C, which is more relevant to the development of cardiovascular disease.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Progress in the Research and Development of Anti-COVID-19 Drugs. (Pubmed Central) - Aug 1, 2020
We also discussed the strategies of the development of anti-COVID-19 drugs in the future. Our review provides a novel insight into the future development of a safer, efficient, and toxic-less anti-COVID-19 drug.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria. (Pubmed Central) - Jul 31, 2020
Previous work showed that gag-protease-derived phenotypic susceptibility to PIs differed between HIV-1 subtype CRF02_AG/subtype G-infected patients who went on to successfully suppress viral replication versus those who experienced virological failure of lopinavir/ritonavir monotherapy as first-line treatment in a clinical trial...There was a moderate correlation between single-round replication efficiency and FC for lopinavir (correlation coefficient 0.32). We found no impact of baseline HIV-1 Gag-protease-derived phenotypic susceptibility on outcomes of PI-based second-line ART in Nigeria.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. (Pubmed Central) - Jul 30, 2020
The two-way interaction between COVID-19 and diabetes mellitus sets up a vicious cycle wherein COVID-19 leads to worsening of dysglycemia and diabetes mellitus, in turn, exacerbates the severity of COVID-19. Thus, it is imperative that people with diabetes mellitus take all necessary precautions and ensure good glycemic control amid the ongoing pandemic.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Clinical trials for the prevention and treatment of COVID-19: current state of play. (Pubmed Central) - Jul 30, 2020
We have grouped these trials into four categories: prophylaxis; treatment of outpatients with mild COVID-19; treatment of hospitalised patients with moderate COVID-19; and treatment of hospitalised patients with moderate or severe disease. The most common therapeutic agent being trialled currently is hydroxychloroquine (24 trials with potential sample size of over 25 000 participants), followed by lopinavir-ritonavir (seven trials) and remdesevir (five trials) There are many candidate drugs in pre-clinical and early phase development, and these form a pipeline for future large clinical trials if current candidate therapies prove ineffective or unsafe.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Lopinavir-ritonavir for COVID-19: A living systematic review. (Pubmed Central) - Jul 30, 2020
For severe and critical patients with COVID-19, lopinavir/ritonavir might play a role in improving outcomes, but the available evidence is still limited. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon.
- |||||||||| favipiravir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, PK/PD data, Review, Journal: Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. (Pubmed Central) - Jul 29, 2020
Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.
- |||||||||| So Remdesivir,Dexamethasone,Hydroxychloroquine and chloroquine,Azithromycin,Convalescent plasma,Tocilizumab ( For DMARD), lopinavir/ritonavir, oseltamivir, favipiravir, colchicine & Ivermectin are being studied! We’re back to the drawing board,haggling for the wonder drug HCQ! (Twitter) - Jul 29, 2020
- |||||||||| Intron A (interferon α-2b) / Merck (MSD), Biogen, ibuprofen / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Journal: A COVID-19 patient with multiple negative results for PCR assays outside Wuhan, China: a case report. (Pubmed Central) - Jul 29, 2020
A combination of patient's exposure history, clinical manifestations, laboratory tests, and typical imaging findings plays a vital role in making preliminary diagnosis and guide early isolation and treatment. Repeat swab tests are helpful in diagnosis for this kind of patients.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. (Pubmed Central) - Jul 24, 2020
Conduction disorders, heart failure and mortality have been reported with the use of these drugs. It is important to have a knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.
- |||||||||| ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Review, Journal: Can mesenchymal stem cell therapy be the interim management of COVID-19? (Pubmed Central) - Jul 24, 2020
Recent studies have shown that MSC-therapy significantly dampens the cytokine storm in critically ill COVID-19 patients. This communication endows with the insight of stem cell therapy and summarizes the recent studies on COVID-19 patients.
- |||||||||| remdesivir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir. (Pubmed Central) - Jul 24, 2020
This communication endows with the insight of stem cell therapy and summarizes the recent studies on COVID-19 patients. Based on the statistical issues and lessons learned from the recent three clinical trials on COVID-19 treatments, we suggest more appropriate approaches for the design and analysis for ongoing and future COVID-19 trials.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
Review, Journal: Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. (Pubmed Central) - Jul 24, 2020
Considering drug-drug interactions and adverse effects of medications used for the treatment of COVID-19, such as QT prolongation, the dose reduction of some immunosuppressants or avoidance is recommended in transplant recipients with COVID-19. Thus, this narrative review describes clinically important considerations about the treatment of COVID-19 and immunosuppressive regimens regarding modifications, side effects, and interactions in adult kidney or liver allograft recipients.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, PK/PD data, Journal: Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics. (Pubmed Central) - Jul 21, 2020
However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case-report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
Review, Journal: COVID-19 Comes 40 Years After AIDS - Any Lesson? (Pubmed Central) - Jul 19, 2020
Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic.
- |||||||||| lopinavir/ritonavir / Generic mfg.
[VIRTUAL] A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE COVID-19 ASSOCIATED LIVER INJURY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_5470;
Our finding suggest Lopinavir/ritonavir is potentially hepatotoxic. As severe COVID-19 and drug-induced liver injury are more common in elderly, we recommend monitoring of liver function when Lopinavir/ritonavir is used in subjects with severe COVID-19.
- |||||||||| lopinavir/ritonavir / Generic mfg.
[VIRTUAL] A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE COVID-19 ASSOCIATED LIVER INJURY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3494;
Our finding suggest Lopinavir/ritonavir is potentially hepatotoxic. As severe COVID-19 and drug-induced liver injury are more common in elderly, we recommend monitoring of liver function when Lopinavir/ritonavir is used in subjects with severe COVID-19.
- |||||||||| lopinavir/ritonavir / Generic mfg.
[VIRTUAL] A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE COVID-19 ASSOCIATED LIVER INJURY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1510;
Our finding suggest Lopinavir/ritonavir is potentially hepatotoxic. As severe COVID-19 and drug-induced liver injury are more common in elderly, we recommend monitoring of liver function when Lopinavir/ritonavir is used in subjects with severe COVID-19.
|
